




Dear colleague,

Thank you for your continued contribution to the DOAC-CVT study!

In this newsletter you can find relevant information about the study.

Inclusion rate

On July 12, 2023 the 500th patient was included in DOAC-CVT by our colleagues from Istanbul Faculty of Medicine (see below). Currently we have **514** included patients from **23** participating countries. Based on the current inclusion rate, we hope to have 600 inclusions by January 2024!



The 500th patient was included by Nilüfer Yeşilot and Mine Sezgin from Istanbul Faculty of Medicine!





Important messages

Patient recruitment was initially planned until January 2024. Since recruitment is going so well, we plan to continue recruitment in the DOAC-CVT study for at least two more years. **Please note that the data of patients included until January 2024 will be analyzed and published as originally planned.**

Goals of the extension study will be to:

- Have a larger sample size to compare DOACs to VKAs. Based on the current inclusion rate we expect around 1200 patients by January 2026.
 - Add new research questions (e.g. on residual symptoms).
 - Strengthen global collaboration.
-

The study protocol is currently being revised to describe the extension of the recruitment period. The revised study protocol will be send to all DOAC-CVT investigators as soon as possible. If you expect any difficulties with your local ethical committee, please contact us.




The manuscript describing the DOAC-CVT Study Protocol has recently been **accepted** for publication in Frontiers in Neurology.

The abstract of the article has already been published on the website ([click here to access the article](#)), the full article will follow soon.



Top recruiting countries

The most actively recruiting countries are: the Netherlands, India, and China. Below you can find a graph of all recruiting countries. Huge thanks to all involved investigators!



New centers

The following centers have recently started patient recruitment: AZ Damiaan (Belgium), NYC Health + Hospitals/Kings County (USA), AUSL-IRCCS Reggio Emilia (Italy), Universidade Federal de Alagoas (Brazil), and Universidade Federal da Bahia (Brazil).

Thank you for your contribution! We look forward to a successful collaboration.



Important messages

1. We kindly want to remind everyone that the **6-month follow-up visit** is the time-point of the primary outcome of the study. It is therefore crucial that the **6-month follow-up** questions are completed for every patient.

2. Please provide as many details as possible about “events of interest”, including any relevant correspondence and imaging reports. Events of interest are: **bleeding events, venous or arterial thrombotic events, seizures, and new hospital admissions.** These events will be adjudicated by our adjudication committee.

3. We would like to collect the most recent recruitment logs again from all participating centers. **Please send us your updated recruitment log** with more information about patients who were excluded from the study.



Anita van de Munckhof (study coordinator):
a.a.vandemunckhof@amsterdamumc.nl
Jonathan Coutinho (Principal Investigator):
j.coutinho@amsterdamumc.nl

